No business profile yet.
Size Scinopharm Taiwan (1789.TW) is a Taiwan Health Care company (Biotechnology) with a market value of $435M, the 474th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$18.75 on 18 Nov 2026.
Performance Over six months the shares fell 1.8%, against -19.5% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue fell 4.8% over the last twelve months (peer median -1.4%); the operating margin is -3.6% (peer median -17.2%).
Valuation It trades at 39.4× forward earnings against a peer median of 30.1× (2nd most expensive of 5).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 6.0 points below its cost of capital (5.0% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$3.04B | NT$3.16B | NT$3.41B | NT$3.19B | NT$3.26B |
| Revenue growth | — | -7% | +7% | -2% | — |
| Gross profit | NT$727M | NT$988M | NT$1.21B | NT$1.13B | NT$1.15B |
| EBITDA | NT$405M | NT$626M | NT$809M | NT$776M | NT$845M |
| Net income | NT$16.7M | NT$137M | NT$339M | NT$287M | NT$353M |
| Free cash flow | NT$512M | NT$306M | NT$471M | -NT$37.2M | NT$530M |
| Capital expenditure | NT$204M | NT$298M | NT$300M | NT$285M | NT$250M |
| Total debt | NT$902M | NT$763M | NT$677M | NT$621M | NT$678M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1789.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.8% | -13.3% | 4th highest of 21 |
| 6-month return | -1.8% | -19.5% | 5th highest of 21 |
| Distance from 52-week high | -35.6% | -45.7% | 5th highest of 21 |
| Revenue growth (TTM) | -4.8% | -1.4% | 8th lowest of 18 |
| Operating margin | -3.6% | -17.2% | 7th highest of 17 |
| Forward P/E | 39.4× | 30.1× | 2nd most expensive of 5 |
| Growth the price implies (Req g, 7 yrs) | 2.1% | 4.0% | 3rd least demanding of 6 |
| Growth delivered (Del g) | +0.5% | +38.9% | 2nd lowest of 5 |
| Hurdle (Req g minus delivered) | +1.6 pp | -32.4 pp | 2nd most demanding of 5 |
| ROIC minus cost of capital | -6.0 pp | -11.2 pp | 7th highest of 16 |
| EV / EBITDA | 29.8× | n/a | — |
| Net debt / EBITDA | -5.5× | -0.6× | 2nd least indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 39.4× | 2.1% | +0.5% |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 33.9× | 7.7% | +7.3% |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | n/a | n/a | n/a |
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |
| Prothena PRTA | United States | $429M | -11% | +347% | -73% | n/a | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $428M | -11% | +230% | 56% | 10.2× | -19.5% | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $427M | +11% | +13% | 47% | 26.2× | 5.3% | +70.5% |
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | n/a | n/a | n/a |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $424M | -8% | +44% | -5% | 170.0× | n/a | n/a |
| Shanghai ZJ Bio-Tech 688317.SS | China | $422M | -22% | -10% | -72% | n/a | 4.0% | -62.3% |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | n/a | n/a | n/a |
| Candel Therapeutics CADL | United States | $417M | -31% | n/a | n/a | n/a | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $416M | -53% | -45% | -2,884% | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $416M | -34% | -1% | 26% | n/a | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $416M | +1% | n/a | n/a | n/a | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | n/a | n/a | n/a |
| Shattuck Labs STTK | United States | $455M | -28% | -100% | n/a | n/a | n/a | n/a |
| Shanghai Obio Technology (Group) 688238.SS | China | $414M | -5% | +20% | -79% | n/a | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $410M | -35% | +1,418% | 26% | n/a | -15.3% | +197.3% |